The ZEISS CT LUCIA 621P/PY is a new generation of aspheric, monofocal, hydrophobic C-loop intraocular lens (IOL) featuring the patented ZEISS Optic (ZO) asphericity concept, designed to provide exceptional vision for a broad variety of eyes. Due to its architecture, this fully preloaded IOL enables
Polypoidal choroidal vasculopathy (PCV) has historically been considered a subtype of neovascular age-related macular degeneration (nAMD). It is characterised by recurrent serosanguinous maculopathy,
It was a case of third time lucky for the 2021 Glaucoma New Zealand (GNZ) Symposium. After two postponements over the past year, the symposium successfully went ahead at Alexandra Park in Auckland on 16 May.
Counties Manukau ophthalmologist Dr Jim Stewart has made a heartfelt plea for shorter referrals from optometrists for their glaucoma patients.
Recurrent nAMD after discontinuation of VEGF inhibitors managed in a treat-and-extend regimen
I have been in hospital. I have been counting my blessings, thankful to be in the hands of people who know what to do when things go wrong. I have been counting blessings not just for me but for all of us, lying there in hospital, watching all those immensely capable doctors, nurses, specialists and
Central serous chorioretinopathy (CSCR) is the fourth most common retinal disease¹. But unlike other common retinal diseases, CSCR commonly affects working-age people and can result in significant morbidity. Although many cases of CSCR resolve spontaneously, persistent subretinal fluid in CSCR beyon
All practices should have a business plan, which for small or medium-sized practices could be as simple as a one-page document. A larger and more complex practice with multiple revenue streams will likely have a more comprehensive plan, with several contributors providing input. The benefits include
This year’s worldwide celebration of orthoptics is approaching, with 21 member countries of the International Orthoptic Association planning to promote the uniqueness of orthoptists’ work on the first Monday in June (coinciding with the Queen’s birthday public holiday in New Zealand).
A healthy 40-year-old male presented with a one-week history of blurred central vision in his right eye. He had no medical history of note. His left eye was mildly amblyopic. Visual acuity at presentation was counting fingers in the right eye and 6/12 in the left eye. Anterior segments were normal a
The use of corticosteroids in ophthalmology was first introduced in the 1950s by Gordon and McLean1. Corticosteroids exert their anti-inflammatory effects via the inhibition of arachidonic acid and
Made possible with support from Blind Low Vision NZ (BLVNZ), this year’s Low Vision Day at Auckland University was an amazing opportunity for BOptom students like us to interact directly with low vision patients and specialists. Throughout the day, not only were our clinical skills put to the test b